Molecule Holdings EBIT

Molecule Holdings posts a EBIT of $-2.9M as of July 2023. That compares with $-3.3M in the prior-year period — up 11.7% year over year. That is below the sector sector average of $2.6T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Molecule Holdings's EBIT was $-3.3M. The latest reading is $-2.9M — a 11.7% year-over-year increase (period ending July 2023). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a EBIT near $2.6T is typical. Molecule Holdings's $-2.9M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Molecule Holdings's financial statement story. At $-2.9M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for EVRRF's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $2.6T), and (3) consistency with growth and profitability. This page covers the first two; Molecule Holdings's other metric pages and overview cover the third.